FDA approves first drug to specifically treat giant cell arteritis

The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559791.htm

Source: Food and Drug Administration - May 22, 2017 Category: American Health Source Type: news

More News: Actemra | American Health | Food and Drug Administration (FDA) | Vasculitis